ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 425,76
-0,73%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) Actualités

MNKD

MannKind (MNKD)

MannKind Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MNKD
DateHeureSourceTitreSymboleSociété
01/05/202422h00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412h05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412h05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202412h00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
26/03/202421h05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
11/03/202411h05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
05/03/202412h05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
04/03/202419h01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
27/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
27/02/202422h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
20/02/202412h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
15/02/202412h05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/01/202412h05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
28/12/202312h00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
15/12/202322h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
07/11/202322h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Third Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
06/11/202312h15GlobeNewswire Inc.MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesNASDAQ:MNKDMannKind Corporation
31/10/202321h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023NASDAQ:MNKDMannKind Corporation
30/10/202311h15GlobeNewswire Inc.MannKind Expands Patent Portfolio With New Clofazimine Formulation PatentNASDAQ:MNKDMannKind Corporation
04/10/202303h00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MNKDMannKind Corporation
23/08/202322h52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MNKDMannKind Corporation
07/08/202322h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Second Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
01/08/202312h00GlobeNewswire Inc.MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
31/07/202322h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023NASDAQ:MNKDMannKind Corporation
22/06/202312h05GlobeNewswire Inc.MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)NASDAQ:MNKDMannKind Corporation
11/06/202314h05GlobeNewswire Inc.Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing MilestoneNASDAQ:MNKDMannKind Corporation
30/05/202322h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MNKDMannKind Corporation
26/05/202323h59Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:MNKDMannKind Corporation
24/05/202314h30GlobeNewswire Inc.Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical OfficerNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
LR
Legrand
EU
AF
Air FranceKLM
EU
PX4
SBF 120
NASDAQ
AMZN
Amazon.com
EU
DG
Vinci
EU
CAP
Capgemini
NYSE
KO
Coca Cola
NYSE
NKE
Nike
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
MRK
Merck
EU
VK
Vallourec
NASDAQ
GOOGL
Alphabet
EU
RI
Pernod Ricard
EU
BNP
BNP Paribas
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés